Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC

Status Recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of weekly administered combination of docetaxel/cisplatin and docetaxel/oxaliplatin in chemotherapy-naïve patients with advanced gastric cancer. The primary endpoint will be the response rate.

Clinical Trial Description

Gastric cancer is the most frequently occurring malignancy in Korea, and is one of the main causes of cancer death. While treatment options for AGC have expanded in recent years to include newer agents such as taxanes, irinotecan and oxaliplatin, myelosuppression remains a problem. Recently, weekly schedule of docetaxel is appealing due to limited incidence of severe myelosuppression compared with standard 3-weekly regimen. This altered toxicity profile suggests a potential for better tolerance and increased dose intensity. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00510107
Study type	Interventional
Source	Gachon University Gil Medical Center
Contact	Dong Bok Shin, MD, PhD
Phone	82 32 460 3682
Email	dbs@gilhospital.com
Status	Recruiting
Phase	Phase 2
Start date	July 2007
Completion date	July 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03313700` - Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer	N/A
Recruiting	`NCT05645198` - The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy	Phase 4
Completed	`NCT03549494` - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction	Phase 2
Completed	`NCT00144378` - Irinotecan Versus Only Best Supportive Care for Gastric Cancer	Phase 3
Completed	`NCT00935779` - Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer	N/A
Completed	`NCT00290966` - Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer	Phase 2/Phase 3
Recruiting	`NCT03348150` - Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.	Phase 3
Not yet recruiting	`NCT06085677` - The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
Recruiting	`NCT02969122` - Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor	N/A
Completed	`NCT01482299` - RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression	Phase 2
Active, not recruiting	`NCT03760822` - Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients	Phase 2
Recruiting	`NCT00509964` - Second-Line Irinotecan vs. ILF for AGC	Phase 2
Completed	`NCT04889859` - Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy	N/A
Completed	`NCT03071237` - The Origin of Infrapyloric Artery
Recruiting	`NCT05184803` - A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer	Phase 2
Completed	`NCT05714878` - Multimodal Prehabilitation for Resectable Gastric Cancer	N/A
Completed	`NCT00142038` - Docetaxel and Capecitabine in Advanced Gastric Cancer	Phase 2
Not yet recruiting	`NCT04056260` - ICG-NIR Guided Lymph Node Dissection in Gastric Cancer	N/A
Recruiting	`NCT03065257` - Endoscopic Resection Multicenter Registry	N/A
Recruiting	`NCT04744649` - Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial	Phase 2